Metabolisches Tumorvolumen nach zwei Zyklen Chemotherapie bei Patienten mit Hodgkin-Lymphom im fortgeschrittenen Stadium: Analyse der Phase-III-Studien HD18 und HD21 der Deutschen Hodgkin Studiengruppe

Nuklearmedizin 2025; 64(01): 44-45
DOI: 10.1055/s-0045-1804281

Abstracts │ NuklearMedizin 2025

Leuchtturm-Vorträge

Beste Abstracts

K S Roth

¹University Hospital Cologne, Department of Nuclear Medicine, Köln, Deutschland

,

H Kaul

²University Hospital Cologne, German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Köln, Deutschland

,

G Schneider

²University Hospital Cologne, German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Köln, Deutschland

,

M Fuchs

²University Hospital Cologne, German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Köln, Deutschland

,

H Eich

³University Hospital of Muenster, Department of Radiotherapy, Münster, Deutschland

,

J Rosenbrock

⁴University Hospital Cologne, Department of Radiotherapy, Köln, Deutschland

,

C Baues

⁵Marienhospital Herne, Ruhr University Bochum, Department of Radiation Oncology, Bochum, Deutschland

,

A Drzezga

¹University Hospital Cologne, Department of Nuclear Medicine, Köln, Deutschland

,

L van Heek

¹University Hospital Cologne, Department of Nuclear Medicine, Köln, Deutschland

,

M Dietlein

¹University Hospital Cologne, Department of Nuclear Medicine, Köln, Deutschland

,

P Borchmann

²University Hospital Cologne, German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Köln, Deutschland

,

J Ferdinandus

²University Hospital Cologne, German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Köln, Deutschland

,

C Kobe

¹University Hospital Cologne, Department of Nuclear Medicine, Köln, Deutschland